Research
Energy balance
Tirzepatide has been approved by the FDA for treating T2D and managing chronic weight in overweight or obese patients.
Healthcare providers can confidently prescribe tirzepatide for eligible patients based on FDA approval.
StrongSupportsmedium confidence
Therefore, it has been approved by the Food and Drug Administration (FDA) for treating T2D and managing chronic weight in overweight or obese patients.
Why this rating
FDA approval is a strong indicator of efficacy and safety.
Source
Tirzepatide in Treating Metabolic Disorders
Shulin Wei et al. · International Journal of Drug Discovery and Pharmacology · 2024
DOI 10.53941/ijddp.2024.100023
reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →